Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Advances such as triple agonists, gene editing, and microbiome therapy offer hope for metabolic diseases, but global access ...

Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

British Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.

US pharma major Eli Lilly has announced top-line results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III ...